Table 3.
Characteristics of retreatment within 8 weeks following initial treatment with laser or intravitreal anti-VEGF, stratified by postmenstrual age at initial treatment.
PMA, post-menstrual age; anti-VEGF, anti-vascular endothelial growth factor
| PMA < 36 weeks | PMA >= 36 weeks | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
Laser
(N = 368 eyes) |
Anti-VEGF
(N = 90 eyes) |
p value |
Laser
(N = 635 eyes) |
Anti-VEGF
(N = 74 eyes) |
p value |
Laser
(N = 1003 eyes) |
Anti-VEGF
(N = 164 eyes) |
p value | |
| # of retreatments | 0.46 | 0.07 | 0.10 | ||||||
| 0 | 327 (88.9%) | 76 (84.4%) | 603 (95.0%) | 61 (82.4%) | 930 (92.7%) | 137 (83.5%) | |||
| 1 | 40 (10.9%) | 12 (13.3%) | 29 (4.6%) | 13 (17.6%) | 69 (6.9%) | 25 (15.2%) | |||
| 2 | 1 (0.3%) | 2 (2.2%) | 3 (0.5%) | 0 (0.0%) | 4 (0.4%) | 2 (1.2%) | |||
| Retreatment rate | 41 (11.1%) | 14 (15.6%) | 0.45 | 32 (5.0%) | 13 (17.6%) | 0.053 | 73 (7.3%) | 27 (16.5%) | 0.03 |
| First retreatment type | 0.06 | 0.22 | 0.31 | ||||||
| Laser | 37 (90.2%) | 7 (50.0%) | 24 (75.0%) | 12 (92.3%) | 61 (83.6%) | 19 (70.4%) | |||
| Anti-VEGF | 4 (9.8%) | 7 (50.0%) | 8 (25.0%) | 1 (7.7%) | 12 (16.4%) | 8 (29.6%) | |||